2-MMC
2-methylmethcathinone
Viewing r1 — May 8, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
2-MMC (2-methylmethcathinone) — ortomephedrone — is a synthetic stimulant of the substituted cathinone class. It is the ortho-positional isomer of mephedrone, distinguished by shorter duration and weaker empathogenic character. 2-MMC is a presumed non-selective monoamine releasing agent, producing its effects by forcing dopamine, norepinephrine, and serotonin out of nerve terminals.[1][2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
amphetamine, methamphetamine, MDMA +3 moreamphetamine, methamphetamine, MDMA, 3-MMC, mephedrone, cocaine show less
First detected on the European drug market in Germany in 2013, 2-MMC emerged as suppliers sought to circumvent bans on mephedrone and later 3-MMC.[3] Following successive prohibitions, the compound surged as a direct market replacement — 83.4% of all EU seizure cases occurred in 2024 alone.[3] EU-wide drug control took effect in January 2026, though drug checking in 2024 found that half of samples sold as 3-MMC actually contained 2-MMC.[3]
Subjective effects include stimulation, euphoria, sociability enhancement, appetite suppression, and wakefulness.[4] The experience is that of a restless, drive-oriented stimulant — sharper and more compulsive than mephedrone but with less emotional warmth, dominated by an intense compulsive redosing urge that users describe as the defining feature of a session.[5] Anxiety, tachycardia, and a pronounced post-use crash with dysphoria and fatigue are common unsought effects.
2-MMC's high dopamine-to-serotonin activity ratio, short duration, and intense redosing compulsion place it in a high-risk category for psychological dependence.[2][5] The short action drives binge patterns in which escalating doses compound cardiovascular strain[6] and post-session monoamine depletion; treatment-seeking for the closely related 3-MMC rose tenfold in the Netherlands between 2021 and 2023.[5] No controlled human studies have been conducted — the entire evidence base consists of forensic detection, class-level pharmacology, and unverified user reports.
History[edit]
Discovery
2-MMC entered the European drug market through isomer substitution — the practice of shifting a single ring substituent to circumvent existing drug controls.[7][8] After mephedrone (4-MMC) was banned across most EU member states beginning in 2010, suppliers pivoted to the meta- and ortho-substituted isomers. 2-MMC was first detected in Germany in 2013, with the earliest documented seizure — roughly 100 grams of powder — occurring in Stockholm in March 2014.[3]
Market proliferation
Two regulatory events catalyzed 2-MMC's spread. China placed it under national drug control in October 2015, temporarily disrupting supply and shifting production to Indian manufacturers routed through the Netherlands.[3] Then the Netherlands prohibited 3-MMC in October 2021, and 2-MMC emerged as its immediate replacement. Of 1,900 total EU seizure cases, 1,587 (83.4%) occurred in 2024 alone.[3] Systematic mislabelling compounded the problem: drug checking services in the first half of 2024 found that 50% of samples sold as 3-MMC actually contained 2-MMC.[3]
Prohibition and current status
EU Delegated Directive 2025/2062 placed 2-MMC under EU-wide drug control on 12 January 2026, with member states required to implement national legislation by July 2026.[9][3] The directive represents the EU's attempt to close the isomer substitution loophole that has driven successive waves of methylmethcathinone variants across the European market.
The name ortomephedrone reflects 2-MMC's structural relationship to mephedrone — the prefix orto- (ortho) denotes the 2-position of the methyl substituent on the phenyl ring, distinguishing it from para-substituted mephedrone. On unregulated markets the compound frequently circulates under the 3-MMC label: forensic analysis confirmed that 12 of 15 Belgian samples initially attributed to mephedrone through standard testing actually contained 2-MMC.[10] Standard immunoassays and basic mass spectrometry struggle to differentiate the positional isomers,[7] making the compound a persistent identification challenge for both users and clinicians.
Chemistry[edit]
Structure
2-MMC belongs to the substituted cathinone family — β-keto amphetamines — within the broader phenethylamine class. The molecule carries an N-methylamino group at the α-carbon and a methyl group at the ortho (2-) position of the aromatic ring. This ortho placement is the sole structural difference from 3-MMC (meta, 3-position) and mephedrone (para, 4-position): all three are positional isomers sharing identical molecular formulae and weights.
The structural lineage runs: phenethylamine → amphetamine (α-methyl) → cathinone (β-keto) → methcathinone (N-methyl) → 2-methylmethcathinone (ortho-methyl ring substituent).
| IUPAC name | 2-(methylamino)-1-(2-methylphenyl)propan-1-one |
| Molecular formula | C₁₁H₁₅NO |
| Molecular weight (free base) | 177.24 g/mol |
| Molecular weight (HCl salt) | 213.70 g/mol |
Stereochemistry
A single chirality center at the α-carbon generates two enantiomers (R and S). Both forms have been detected in oral fluid samples from confirmed users using enantioselective analysis.[10] No data exist on whether the enantiomers differ in pharmacological activity.
For the closely related mephedrone, the R-enantiomer shows significantly greater reinforcing properties in animal models[11] — whether this pattern extends to 2-MMC is unknown, as steric effects of the ortho-methyl group may alter transporter selectivity.
Physical properties
The hydrochloride salt is a white crystalline powder, highly water-soluble, consistent with other cathinone salts. Analytical reference standards of ≥98% purity are commercially available. No published data exist on stability, degradation pathways, or long-term storage characteristics.
Pharmacology[edit]
Mechanism of action
No binding affinity or functional potency data have been published for 2-MMC at any molecular target. All mechanistic understanding is inferred from the well-studied isomers 3-MMC and mephedrone, and from the broader cathinone pharmacological framework.
Within that framework, 2-MMC is classified as a non-selective monoamine releasing agent. It enters nerve terminals via the DAT (DAT), NET (NET), and SERT (SERT), then reverses their normal function to force monoamines out into the synapse.[1][2][12] The mechanism is analogous to amphetamine and MDMA, though the relative potency at each transporter differs across the cathinone series.
A systematic review found that the 2- and 3-MMC isomers collectively show similar dopaminergic but reduced serotonergic activity compared to mephedrone.[5] This ratio matters: compounds that hit dopamine harder than serotonin tend to be more reinforcing and carry greater abuse liability, while those with stronger serotonin activity (like MDMA) produce more empathogenic effects.[2] The reduced serotonergic activity of 2-MMC predicts weaker empathogenic character and potentially higher abuse liability — though this inference remains untested.
safety citation needed This classification is based entirely on structural analogy. No in vitro transporter assay or functional pharmacology study has been conducted specifically on 2-MMC.
Pharmacokinetics
No controlled human pharmacokinetic studies exist. Bioavailability, time to peak concentration, half-life, and protein binding are all unknown.
Two primary metabolites have been identified in oral fluid samples from confirmed users[10]: nor-2-MMC (formed by removing the N-methyl group) and dihydro-2-MMC (formed by reducing the ketone to a hydroxyl group). Both pathways are consistent with the broader cathinone class.
The specific liver enzymes responsible for 2-MMC metabolism have not been identified. By analogy with 3-MMC, where blocking CYP2D6 and CYP2E1 reduced liver cell toxicity in vitro,[13] these enzymes are the most likely candidates. If confirmed, this would predict meaningful variability between individuals — people who metabolize drugs slowly through CYP2D6 (5–10% of European populations) could experience altered drug exposure and different toxicity profiles.
Neuroscience[edit]
Where it acts
As a presumed dopamine-dominant monoamine releaser,[5] 2-MMC is expected to drive its primary effects through the mesolimbic mesolimbic pathway — dopamine release from the ventral tegmental area to the nucleus accumbens produces the subjective experience of reward, motivation, and psychomotor activation. Concurrent norepinephrine release drives the sympathetic arousal characteristic of the stimulant experience: elevated heart rate, wakefulness, and heightened alertness.
The reduced serotonergic component, relative to mephedrone, predicts less modulation of emotional and social processing circuits. This translates to a more purely stimulant profile — less emotional openness and tactile enhancement, more restless drive.[4]
Why it matters
The most relevant framework is incentive salience theory — the distinction between wanting (dopamine-driven craving) and liking (hedonic pleasure). 2-MMC's high dopamine-to-serotonin ratio positions it as a compound that preferentially drives wanting over liking, predicting the intense compulsive redosing reported for this class.[5] Users may experience powerful craving even as the hedonic return diminishes with each subsequent dose.
Repeated exposure triggers compensatory neuroadaptation: dopamine receptors downregulate, baseline dopamine synthesis drops, and normal mood states begin to feel insufficient — a trajectory consistent with rising treatment-seeking rates for 3-MMC in the Netherlands.[5] Animal data show that concurrent alcohol use approximately doubles cathinone-related neurotoxic damage to dopamine and serotonin systems in the frontal cortex.[14]
Key unknowns include whether the ortho-methyl position produces meaningfully different transporter kinetics than the meta- or para-positions, whether 2-MMC causes lasting dopaminergic neurotoxicity at typical recreational doses, and whether the neuroadaptive changes from repeated use are reversible — and on what timescale.
Subjective Effects[edit]
The subjective character of 2-MMC is that of a dopamine-dominant stimulant with attenuated empathogenic warmth relative to mephedrone. The experience centers on physical and cognitive drive — wakefulness, energy, verbal fluency, sociability — accompanied by euphoria whose intensity is strongly route-dependent, with insufflation producing a sharper rush and oral dosing a more gradual arc. The defining feature of a 2-MMC session, reported consistently across users, is the compound's pronounced compulsive redosing urge[5] — the pharmacology shapes the behavioral pattern as much as the quality of any single dose.
Within the methylmethcathinone series, 2-MMC sits closer to the pure stimulant pole than mephedrone, which occupies a hybrid position between stimulant and empathogen. Compared to amphetamine, it is shorter-acting with a more pronounced euphoric peak but faster hedonic decline — a profile that favors binge patterns over sustained functional use.
Effect Grid
Full stimulant profile emerges — clear euphoria, marked energy increase, and pronounced sociability enhancement with increased talkativeness. Cognitive euphoria and thought acceleration are evident. Focus enhancement may be present, along with motivation enhancement. Music enhancement is reported by some users.
Sympathomimetic effects become apparent: tachycardia, elevated blood pressure, pupil dilation, and appetite suppression are prominent. Bruxism may emerge. Excessive sweating and temperature dysregulation begin at this level. Dry mouth is common.
The compulsive redosing urge becomes noticeable — the short duration of 2-MMC drives a pattern of repeated dosing that is the defining behavioral feature of use at this range. Insomnia is likely for several hours post-dose.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Visual processing acceleration · Visual acuity enhancement · Sound sensitivity · Tinnitus
Dry mouth · Heart rate perception changes · Insomnia · Pupil dilation · Body high · Dehydration sensation · Muscle tension · Physical fatigue · Restlessness · Bruxism · Excessive sweating · Respiratory stimulation · Tactile euphoria · Headache · Nasal congestion · Sexual arousal enhancement · Spontaneous body sensations · Tingling / electric sensations · Motor control enhancement · Dizziness · Laughter fits · Nausea · Trembling · Involuntary body movements · Vomiting
Body high · Dehydration sensation · Muscle tension · Physical fatigue · Restlessness · Bruxism · Excessive sweating · Respiratory stimulation · Tactile euphoria · Headache · Nasal congestion · Sexual arousal enhancement · Spontaneous body sensations · Tingling / electric sensations · Motor control enhancement · Dizziness · Laughter fits · Nausea · Trembling · Involuntary body movements · Vomiting
Motivation enhancement · Pattern recognition enhancement · Focus enhancement · Information processing enhancement · Aesthetic enhancement · Analysis enhancement · Cognitive dysphoria · Cognitive flexibility · Creativity enhancement · Immersion enhancement · Language enhancement · Motivation suppression · Novelty enhancement · Openness enhancement · Thought connectivity · Thought organization · Humor enhancement · Memory enhancement · Thought loops · Cognitive impairment · Confusion · Thought disorganization
Aesthetic enhancement · Analysis enhancement · Cognitive dysphoria · Cognitive flexibility · Creativity enhancement · Immersion enhancement · Language enhancement · Motivation suppression · Novelty enhancement · Openness enhancement · Thought connectivity · Thought organization · Humor enhancement · Memory enhancement · Thought loops · Cognitive impairment · Confusion · Thought disorganization
Emotional enhancement · Empathy enhancement · Irritability · Dysphoria · Emotional lability
Emotional lability
Communication enhancement · Sociability enhancement · Emotional susceptibility · Trust enhancement · Flow state · Ego inflation
Flow state · Ego inflation
Timeline
Initial alertness emerges with mild peripheral stimulation — a faint heart rate increase and subtle restlessness. Effects may be difficult to distinguish from anticipation.
Rising euphoria and energy. Sociability enhancement begins, conversation flows more easily. Appetite suppression starts.
Maximum euphoria and stimulation. Sociability enhancement at its strongest, thought acceleration prominent, appetite absent. Tachycardia and bruxism may be noticeable.
Stimulation persists but euphoria declines. The redosing urge intensifies as hedonic return diminishes. Residual sympathomimetic effects (elevated heart rate, sweating) continue.
Stimulation fades unevenly. Irritability and mild dysphoria emerge. Physical fatigue begins despite residual wakefulness.
Residual fatigue, mild dysphoria, and impaired concentration. Appetite returns. Insomnia may persist despite subjective tiredness.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- Moderate
- Tolerance buildup
- moderate
- Tolerance reset
- 10 days
- Physical
- Negligible
- Psychological
- High
- Compulsive redosing
- High
- Dose escalation
- Moderate
- Cross-tol.
- amphetamine · methamphetamine · MDMA
Toxicity
No lethal dose data, therapeutic index, or controlled toxicology studies exist for 2-MMC in any species. No published case reports attribute a death or serious adverse event to 2-MMC alone. All toxicity assessment derives from data on related cathinones, primarily 3-MMC and mephedrone.
Heart and circulation
Cardiovascular toxicity is the most significant acute danger. A retrospective analysis of 222 cathinone poisonings reported to the Dutch Poisons Information Centre found elevated heart rate, high blood pressure, palpitations, and chest pain as the most common presentations.[6] Serious cardiac events documented across the cathinone class include cardiac arrest (28 published cases), dangerous heart rhythms, heart attacks, and inflammation of the heart muscle.
2-MMC shares the same mechanism of norepinephrine-driven cardiovascular stress.
Liver toxicity
Laboratory studies on 3-MMC show that it damages liver cells through oxidative stress at concentrations within the range expected from human use.[13] The damage appears driven by reactive byproducts generated during metabolism. 2-MMC is expected to share this vulnerability, though direct testing has not been performed.safety citation needed
Brain and nervous system
A systematic review of 76 studies found synthetic cathinones associated with brain swelling, seizures, coma, serotonin syndrome, and excited delirium.[15] Combining cathinones with alcohol roughly doubles the neurotoxic damage to dopamine and serotonin systems in animal models.[14]
Stimulant toxidrome
The expected acute toxicity pattern, based on confirmed 3-MMC data, includes: elevated heart rate (48%), agitation (42%), reduced consciousness (32%), dilated pupils (24%), hallucinations (20%), heavy sweating (12%), seizures (8%), and dangerously high body temperature (6%).[16][17][18] These rates are approximate class estimates for 2-MMC.safety citation needed
Testing cross-reactivity
2-MMC produces false-positive amphetamine results on standard hospital drug screens at concentrations ≥50 μg/mL.[19] Cathinone poisoning may be misidentified as amphetamine use in emergency departments that rely on immunoassay screening without confirmatory testing.
No antidote exists. Emergency treatment is supportive: benzodiazepines for agitation and seizures, active cooling for dangerously high body temperature, and cardiac monitoring.[16]
Psychological risks
Acute psychological distress includes agitation, anxiety, paranoia, and hallucinations — consistent with excessive dopamine activity.[15] User reports describe visual and auditory hallucinations and aggressive behavior at higher doses.[4] Psychotic-spectrum symptoms (paranoid beliefs, persecutory delusions) are documented for the cathinone class and linked to high doses, prolonged use, sleep deprivation, and polydrug combinations.[16]
The post-use crash is expected to include low mood, irritability, fatigue, anhedonia, and depressed mood — the result of temporary monoamine depletion. The compound's short duration and intense redosing urge[5] create a specific risk: binge sessions in which escalating doses compound both acute toxicity and the severity of the subsequent crash.
Treatment-seeking for the closely related 3-MMC rose from 33 to 330 individuals annually in the Netherlands between 2021 and 2023,[5] providing an indirect measure of psychological harms associated with this use pattern. No data exist on whether 2-MMC can trigger lasting psychiatric conditions or whether pre-existing mental health vulnerability increases risk.
Tolerance & dependence
No 2-MMC-specific tolerance or dependence data have been published.
Tolerance to euphoric effects develops through repeated cathinone use, driven by compensatory changes in dopamine receptors. The rate for 2-MMC is uncharacterized. Cross-tolerance with other monoamine releasers — amphetamines, MDMA, 3-MMC, mephedrone — is expected but unquantified.
Dependence: The pharmacological profile — high dopamine activity, short duration, strong compulsive redosing urge — places 2-MMC in the high-risk category for psychological dependence.[2][1] The 2- and 3-MMC isomers produce greater craving and more frequent redosing than mephedrone,[5] a compound already recognized for significant abuse potential. Most people seeking treatment for methylmethcathinone problems also use other substances.[5]
Withdrawal has not been characterized for 2-MMC. By class analogy, it is expected to present as fatigue, excessive sleep, appetite enhancement, low mood, and craving. Physical withdrawal is not life-threatening, but psychological withdrawal — particularly craving and inability to feel pleasure — may be prolonged.[16]
Drug interactions
No interaction data have been published specifically for 2-MMC. All interactions are inferred from its mechanism as a monoamine releasing agent.safety citation needed
Monoamine oxidase inhibitors (MAOIs — including phenelzine, tranylcypromine, moclobemide, and plant-derived harmine/harmaline) represent the most dangerous combination. MAOIs prevent the breakdown of monoamines; combined with a releaser, the result is catastrophic monoamine accumulation that can cause fatal blood pressure spikes, serotonin syndrome, and extreme hyperthermia. This interaction is life-threatening.
Serotonin-active medications (SSRIs, SNRIs, triptans, tramadol, lithium) carry additive serotonergic risk. Although 2-MMC's reduced serotonin activity relative to mephedrone[5] may partially attenuate this risk, serotonin syndrome remains possible — particularly with strong serotonergic co-medications or at high doses.
Other stimulants (amphetamines, cocaine, MDMA, other cathinones) produce additive cardiovascular strain and compound neurotoxicity. Combining 2-MMC with MDMA would produce dual-source serotonin release with elevated serotonin syndrome risk.
Alcohol is the most common co-ingestant: approximately 95% of cathinone users report concurrent alcohol use.[14] In animal models, alcohol combined with mephedrone produces roughly double the neurotoxic damage compared to mephedrone alone.[14] Alcohol also impairs judgment, increasing the likelihood of compulsive redosing.
GHB/GBL combined with stimulant cathinones is documented in chemsex fatalities involving 3-MMC.[18] The stimulant masks GHB's sedative effects, enabling accidental depressant overdose; when the stimulant wears off, respiratory depression may emerge.
CYP2D6 inhibitors (fluoxetine, paroxetine, quinidine, bupropion) may alter 2-MMC metabolism, potentially increasing drug exposure and changing the balance between parent compound and toxic metabolites.[13]
Contraindications
No substance-specific contraindication data exist. All contraindications are mechanism-based.
Heart conditions — including coronary artery disease, heart failure, uncontrolled high blood pressure, structural heart defects, and history of abnormal heart rhythm — are an absolute contraindication. Cathinone-induced norepinephrine release drives dose-dependent increases in heart rate and blood pressure; serious cardiac events are documented in the class.[6]
Concurrent MAOI use is an absolute contraindication due to risk of fatal blood pressure crisis and serotonin syndrome.
Seizure disorders are a relative contraindication. Seizures occur in approximately 8% of cathinone poisoning presentations,[18] and monoamine releasers lower seizure threshold.
Liver impairment is a relative contraindication. If the expected metabolic enzymes are confirmed, impaired liver function would alter drug clearance and potentially increase exposure to toxic byproducts.[13]
Mental health vulnerability — active psychosis, bipolar disorder, severe anxiety disorders — is a relative contraindication. Dopaminergic stimulation can precipitate or worsen psychotic symptoms, manic episodes, and panic attacks.[15]
Pregnancy and breastfeeding are absolute contraindications. No reproductive data exist for 2-MMC, but stimulants as a class carry risks of reduced blood flow to the placenta, fetal distress, and preterm labor.safety citation needed
Hot environments, vigorous activity, and dehydration compound the cathinone-class risk of dangerously high body temperature, documented in 6% of 3-MMC poisoning presentations.[18]
Harm Reduction[edit]
Forms & Identification
The central harm reduction challenge with 2-MMC is identity uncertainty. Standard reagent kits and basic lab tests cannot distinguish between the methylmethcathinone positional isomers (2-MMC, 3-MMC, and mephedrone) — all three produce identical reagent color reactions. Only advanced analytical services (GC-MS, LC-MS/MS, or NMR) can confirm which isomer is present.
What this means in practice: any powder sold as 3-MMC or mephedrone may contain 2-MMC, and vice versa. Drug checking data confirm this is not a theoretical concern — it is the market norm.[3] Use drug checking services with advanced analytical capability wherever available.
Guidelines
- Test all material with an advanced drug checking service before use — reagent kits cannot distinguish the methylmethcathinone isomers
- Pre-measure and separate doses before beginning a session; do not carry your full supply on your person
- Set a firm limit on total doses and session duration before starting — the redosing urge is the primary risk vector
- Start with a low oral dose and wait for full onset before considering re-administration
- Keep hydrated but avoid excessive water intake — moderate, regular sips
- Have a trusted person present who is not using and can monitor time, temperature, and behavior
- Eat a light meal beforehand; appetite suppression during the session makes retrospective nutrition harder
- Plan for the comedown: have food, water, and a comfortable rest space ready
Set & Setting
The short duration and intense redosing urge are the defining risk factors for 2-MMC use. Plan for this: sessions easily escalate beyond intended limits when each dose wears off quickly and the compulsion to take more is strong.
A calm, familiar environment with trusted people present reduces the risk of anxiety, paranoia, and impulsive redosing. Avoid hot, crowded, or physically demanding settings — these compound the risk of dangerously elevated body temperature and cardiovascular strain.
Aftercare & integration. The comedown from 2-MMC involves monoamine depletion — the brain's supply of dopamine, norepinephrine, and serotonin is temporarily reduced. Expect low mood, fatigue, irritability, and difficulty feeling pleasure for 1–3 days after use.
Physical recovery: Prioritize sleep, even if it feels difficult initially. Eat nutritious meals — the appetite suppression during use means the body needs replenishment. Stay hydrated. Light exercise (walking, stretching) can support mood recovery but avoid anything strenuous for 24–48 hours.
Psychological recovery: The crash period is temporary. Intense cravings to redose during the comedown are a pharmacological effect, not a personal failing — recognize them as the drug's signature and let them pass. If low mood, anxiety, or cravings persist beyond a week, consider speaking to a healthcare provider.
Recovery & Support
The high compulsive redosing urge and short duration of 2-MMC create a use pattern that can escalate quickly from occasional sessions to regular binge use. Treatment-seeking for the closely related 3-MMC rose tenfold in the Netherlands in just two years,[5] suggesting this pattern is widespread.
Warning signs of problematic use include: using more frequently or in larger amounts than intended, difficulty stopping once a session begins, neglecting responsibilities or relationships, persistent low mood between sessions, and continued use despite negative consequences.
Support resources include addiction helplines, harm reduction services, and mental health professionals experienced with stimulant use disorders. Cognitive behavioral therapy and motivational interviewing have evidence for stimulant dependence. Most people seeking treatment for methylmethcathinone use also use other substances[5] — comprehensive assessment covering all substance use is more effective than addressing one compound in isolation.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
- Chest pain or tightness
- Seizure or loss of consciousness
- Body temperature you can feel through clothing (extreme overheating)
- Severe confusion, aggression, or complete disconnection from reality
- Breathing difficulties
Any of these requires immediate action — they distinguish a medical emergency from an uncomfortable but manageable experience.
Immediate steps:
- Call emergency services immediately
- Do not leave the person alone
- If unconscious and breathing, place in the recovery position (on their side)
- If overheating, move to a cool area, remove excess clothing, apply cool (not ice-cold) water
- Do not restrain unless there is immediate danger of self-harm
- Do not induce vomiting
What to tell the dispatcher:
Name the substance (or "a stimulant cathinone" if uncertain), the amount taken, the time of last dose, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
No reversal agent exists for cathinone poisoning. Treatment is entirely supportive.
Legal Status[edit]
2-MMC occupied a legal grey area in most jurisdictions for over a decade following its first detection in 2013, exploiting the positional isomer loophole that allowed it to evade controls targeting mephedrone and later 3-MMC. This period ended with EU-wide control in January 2026.
EU Delegated Directive 2025/2062 subjects 2-MMC to drug control across all member states,[9] with national implementation required by 12 July 2026.[3]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| European Union | Controlled substance (EU Delegated Directive 2025/2062) | EU-wide control from 12 January 2026; national implementation deadline 12 July 2026[9] |
| United Kingdom | Controlled under Psychoactive Substances Act 2016 | Blanket ban on psychoactive substances; production, supply, and import prohibited; simple possession not an offence under PSA unless in a custodial institutioncitation needed |
| United States | Not specifically scheduled | Potentially prosecutable under the Federal Analogue Act (21 USC §813) if demonstrated to be substantially similar to a Schedule I cathinone and intended for human consumptioncitation needed |
| China | Controlled substance | National drug control since October 2015[3] |
| Australia | Schedule 9 — Prohibited Substance | Illegal to manufacture, possess, sell, or usecitation needed |
| Netherlands | Controlled (EU implementation pending) | 3-MMC prohibited under Opium Act since October 2021; 2-MMC control expected under EU directive by July 2026[3] |
In the United States, while 2-MMC is not specifically scheduled, the Federal Analogue Act creates potential criminal liability for substances substantially similar to Schedule I compounds when intended for human consumption. Methcathinone is Schedule I and mephedrone has been emergency-scheduled to Schedule I — establishing a structural basis for analogue prosecution. Enforcement is inconsistent and no published court decision has addressed 2-MMC specifically.citation needed
references
- [1] ^abcSimmler LD, Buser TA, Donzelli M, et al. (2012) Pharmacological characterization of designer cathinones in vitro — British Journal of Pharmacology doi:10.1111/j.1476-5381.2012.02145.x
- [2]
- [3]
- [4]
- [5]
- [6] ^abcGroenewegen KL, Gresnigt FMJ, Lonkhuyzen JJN, den Haan C, Franssen EJF, Riezebos RK, Ohana D, de Lange DW (2024) Cardiotoxicity After Synthetic Cathinone Use; Two Cases, A Case Series and Scoping Review — Cardiovascular toxicology doi:10.1007/s12012-024-09832-x